8-K: Biogen Reports Strong Q2 2024 Results and Raises Full Year Guidance

Biogen's second quarter of 2024 saw flat revenue growth but a significant increase in non-GAAP EPS, leading to an improved full-year financial outlook.

Summary

• Biogen reported second quarter 2024 total revenue of $2.5 billion, which was flat year-over-year at actual currency and up 1% at constant currency.
• GAAP diluted EPS was $4.00, a 2% decrease year-over-year, while non-GAAP diluted EPS was $5.28, a 31% increase year-over-year.
• Core pharmaceutical revenue increased by 5% at actual currency and 6% at constant currency year-over-year.
• The company benefited from a $0.52 per share gain from the sale of a priority review voucher.
• Excluding the PRV sale, GAAP diluted EPS declined 14% and non-GAAP diluted EPS increased 18% year-over-year.
• LEQEMBI, Biogen's Alzheimer's drug, generated approximately $40 million in global in-market sales, with $30 million in the U.S.
• SKYCLARYS, a rare disease treatment, achieved $100 million in global revenue.
• ZURZUVAE, another new product, generated $15 million in revenue.
• Biogen completed the acquisition of Human Immunology Biosciences (HI-Bio), expanding its immunology portfolio.
• Full year 2024 non-GAAP EPS guidance was raised to $15.75 to $16.25, representing approximately 9% growth at the mid-point versus 2023.
• Total revenue is now expected to decline by a low-single digit percentage versus 2023, with core pharmaceutical revenue expected to be roughly flat.
• Operating income is expected to grow at a midto high-teen percentage versus 2023.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the raised EPS guidance and strong non-GAAP earnings, but tempered by flat revenue growth and some declines in key product areas. The strategic moves and pipeline development are encouraging.

Positives

• Non-GAAP diluted EPS showed a significant increase of 31% year-over-year.
• Core pharmaceutical revenue experienced solid growth of 5% at actual currency and 6% at constant currency.
• The launch of LEQEMBI is showing accelerated growth with $40 million in global sales.
• SKYCLARYS is demonstrating strong global growth potential with $100 million in revenue.
• The acquisition of HI-Bio expands Biogen's immunology portfolio and late-stage pipeline.
• Full year 2024 non-GAAP EPS guidance has been raised, indicating improved profitability.
• Operating income is expected to grow at a midto high-teen percentage versus 2023.
• The company's Fit for Growth program is delivering significant savings.

Negatives

• GAAP diluted EPS decreased by 2% year-over-year.
• Total revenue was flat year-over-year at actual currency.
• Excluding the PRV sale, GAAP diluted EPS declined 14% year-over-year.
• Total revenue is expected to decline by a low-single digit percentage for the full year 2024.
• Multiple sclerosis product revenue decreased by 5% year-over-year.

Risks

• The company is dependent on sales from its products, and any decline could impact financial results.
• There is uncertainty in developing, licensing, or acquiring new product candidates.
• Failure to compete effectively could impact market share and revenue.
• Difficulties in obtaining and maintaining adequate coverage, pricing, and reimbursement for products could affect sales.
• The company relies on collaborators and third parties, which are outside of its full control.
• There are risks associated with healthcare reforms and commercialization of biosimilars.
• The company faces risks related to intellectual property claims and challenges.
• Clinical trial results may not be replicated in subsequent trials or lead to regulatory approval.
• Adverse safety events or product liability claims could impact the company.
• Technology failures or breaches could disrupt operations.
• There are risks related to management, personnel, and organizational changes.
• The company faces risks of doing business internationally, including currency exchange rate fluctuations.
• There are risks related to investment in manufacturing capacity and access to capital and credit markets.

Future Outlook

Biogen has raised its full-year 2024 non-GAAP EPS guidance and expects operating income to grow at a midto high-teen percentage. Total revenue is expected to decline by a low-single digit percentage, with core pharmaceutical revenue expected to be roughly flat. The company plans to reinvest proceeds from the sale of a priority review voucher into growth initiatives.

Management Comments

• Biogen delivered strong financial performance in the second quarter thanks to solid execution against our business strategy, which is aimed at transforming the Company to deliver sustainable growth.
• We saw continued positive momentum across new product launches and are pleased with the trends we see with key products going into the third quarter.
• We believe we have created a strong midto late-stage development pipeline thanks to reprioritization efforts made last year and key acquisitions like HI-Bio.
• Our Fit for Growth program announced in early 2023 continues to deliver significant savings, allowing us to strategically reinvest a portion back into product launches and the pipeline.

Industry Context

Biogen's results reflect the ongoing challenges and opportunities in the biotechnology sector, particularly in the areas of Alzheimer's disease, rare diseases, and immunology. The company's focus on new product launches and strategic acquisitions aligns with industry trends of seeking growth through innovation and portfolio expansion. The performance of LEQEMBI is being closely watched as a key indicator of success in the Alzheimer's market.

Comparison to Industry Standards

• Biogen's revenue growth is relatively flat compared to some of its peers in the biotechnology industry, which have seen more robust growth in recent quarters. For example, companies like Regeneron and Vertex have reported higher revenue growth rates.
• However, Biogen's focus on cost management and efficiency, as evidenced by its Fit for Growth program, is in line with industry trends of optimizing operations to improve profitability.
• The launch of LEQEMBI is a key area of comparison, with other companies like Eli Lilly also developing Alzheimer's treatments. The market share and sales trajectory of LEQEMBI will be closely compared to these competitors.
• Biogen's acquisition of HI-Bio is similar to other biotech companies seeking to expand their pipelines through strategic acquisitions. The success of this acquisition will be measured against other similar deals in the industry.
• The company's non-GAAP EPS growth of 31% is a positive sign, but it is important to compare this to the growth rates of other companies in the sector to assess its relative performance.

Stakeholder Impact

• Shareholders will benefit from the increased EPS guidance and potential for future growth.
• Employees may see job security and opportunities due to the company's strategic initiatives.
• Patients will have access to new treatments for Alzheimer's, rare diseases, and other conditions.
• Customers will benefit from the company's focus on innovation and product development.
• Suppliers and creditors will have a stable business partner with a strong financial position.

Next Steps

• Biogen will continue to focus on the launch of new products like LEQEMBI, SKYCLARYS, and ZURZUVAE.
• The company will integrate HI-Bio into its operations and advance its late-stage pipeline.
• Biogen will continue to execute its Fit for Growth program to achieve cost savings and reinvest in growth initiatives.
• The company will present clinical data for LEQEMBI at upcoming conferences.
• Eisai will seek CHMP re-examination in the E.U. for LEQEMBI.
• Biogen plans to accelerate proof of concept outcome for anti-tau program (BIIB080).

Key Dates

Keywords

Biogen, BIIB, Pharmaceuticals, Biotechnology, LEQEMBI, SKYCLARYS, ZURZUVAE, HI-Bio, Earnings, Revenue, EPS, Alzheimer's, Rare Disease, Immunology, Biosimilars